Nanomedicine in the Treatment of Diabetes

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(13), С. 7028 - 7028

Опубликована: Июнь 27, 2024

Nanomedicine could improve the treatment of diabetes by exploiting various therapeutic mechanisms through use suitable nanoformulations. For example, glucose-sensitive nanoparticles can release insulin in response to high glucose levels, mimicking physiological insulin. Oral nanoformulations for uptake via gut represent a long-sought alternative subcutaneous injections, which cause pain, discomfort, and possible local infection. Nanoparticles containing oligonucleotides be used gene therapy cell stimulate production β-cells or β-like cells modulate responses T1DM-associated immune cells. In contrast, viral vectors do not induce immunogenicity. Finally, diabetic wound healing, delivery regenerative molecules tissue repair thus provide valuable tool treat this complication. Here, we describe these different approaches with their potential clinical application.

Язык: Английский

---

Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders

Clinical Reviews in Allergy & Immunology, Год журнала: 2025, Номер 68(1)

Опубликована: Фев. 11, 2025

Язык: Английский

---

Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 17, 2025

Treating autoimmune diseases without nonspecific immunosuppression remains challenging. To prevent or treat these conditions through targeted immunotherapy, we developed a clinical-stage nanoparticle platform that leverages the tolerogenic capacity of liver sinusoidal endothelial cells (LSECs) to restore antigen-specific immune tolerance. In vivo efficacy was evaluated in various CD4+ T cell-mediated disease models, including preventive and therapeutic models myelin oligodendrocyte glycoprotein-induced experimental encephalomyelitis (EAE), ovalbumin-sensitized delayed-type hypersensitivity (DTH), spontaneous type 1 diabetes model. Nanoparticle-induced responses were also analyzed adoptive transfers 2D2 transgenic into wild-type mice, followed by administration. The peptide-conjugated nanoparticles displayed uniform size distribution (25-30 nm). Their coupling efficiency for peptides with unfavorable physicochemical properties significantly enhanced proprietary linker technology. Preferential LSEC targeting coupled fluorescently labeled confirmed via intravital microscopy flow cytometry. Intravenous administration reduced severity demyelination EAE, independent prednisone at maintenance doses, suppressed target tissue inflammation DTH Furthermore, prophylactic mixture five autoantigenic lowered hyperglycemia incidence non-obese diabetic mice. Mechanistically, tolerizing effects associated induction regulatory cell anergy, which counteract proinflammatory tissue. Our findings demonstrate peptide-loaded preferentially deliver disease-relevant LSECs, thereby inducing This versatile holds promise clinical application across multiple diseases.

Язык: Английский

---

Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management

Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 12

Опубликована: Март 20, 2025

RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted lot of research on the application technology in treatment CVDs. Despite hurdles off-target effects immune responses, clinical trial outcomes encouraging. This review synthesizes current progress CVDs, examining their mechanisms, advantages, challenges delivery safety. We highlight potential personalized medicine, combination artificial intelligence (AI) bioinformatics advancing therapeutics. The future CVDs is poised significant impact, necessitating continued interdisciplinary collaboration to optimize these treatments ensure patient safety efficacy.

Язык: Английский

---

Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases

Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113641 - 113641

Опубликована: Март 1, 2025

Язык: Английский

---

Unlocking the power of imidazoquinolines: recent advances in anticancer and immunotherapeutic strategies

Future Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 1 - 17

Опубликована: Апрель 15, 2025

The challenges in drug discovery aiming to mitigate cancer progression are the thrust area of scientific research for several decades. Since advent heterocyclic chemistry, programs have made significant achievements that lead development numerous drugs with broad spectrum potencies, contributing both diagnostic and therapeutic advancements. Till date, efforts discover more potent efficient candidates underway minimize adverse side effects existing chemotherapeutics. In view above, small-molecule agonists can interact different immune modulators like toll receptor-7 (TLR-7) TLR-8 being investigated explored. These expected display profound effect on anti-tumoral activity by enhancing production proinflammatory cytokines. Recently, imidazoquinoline derivatives proven TLR agonist activities emerged as promising anticancer therapeutics. With advancements technology evolution new scopes discovery, strategies adopted, particularly help nanotechnology, immune-technology, combination etc., curb various types cancers. Herein, novel therapeutics imidazoquinolines reported last 5 years, their structure-activity relationship along important synthetic schemes agonists, discussed.

Язык: Английский

---

Lipid nanoparticle‐mediated RNA delivery for immune cell modulation

European Journal of Immunology, Год журнала: 2024, Номер 54(12)

Опубликована: Сен. 16, 2024

Lipid nanoparticles (LNPs) have emerged as the preeminent nonviral drug delivery vehicles for nucleic acid therapeutics, exemplified by their usage in mRNA COVID-19 vaccines. As a safe and highly modular platform, LNPs are attractive wide range of applications. In addition to vaccines, being utilized platforms other immunoengineering efforts, especially cancer immunotherapies modulating immune cells functionality via delivery. this review, we focus on methods applications LNP-based immunotherapy five cell types: T cells, NK macrophages, stem dendritic cells. Each these types has wide-reaching but comes with unique challenges barriers. By combining knowledge immunology nanotechnology, can be developed improved targeting transfection, ultimately working toward novel clinical therapeutics.

Язык: Английский

---

Impact of antigen loading in tolerogenic nanoparticles to mitigate Th2-mediated allergic lung inflammation

Drug Delivery and Translational Research, Год журнала: 2024, Номер 14(10), С. 2930 - 2944

Опубликована: Июнь 11, 2024

Язык: Английский

---

The future of genetic medicines delivered via targeted lipid nanoparticles to leukocytes

Journal of Controlled Release, Год журнала: 2024, Номер 376, С. 286 - 302

Опубликована: Окт. 16, 2024

Язык: Английский

---